Stocks Eli Lilly and Co

More

  • Investors usually cash out ahead of a holiday weekend and, in this jittery environment, they found their reasons to sell today: a slew of bleak economic reports and a profit warning from Best Buy.

  • Investors usually cash out ahead of a holiday weekend and, in this jittery environment, they found their reasons to sell today: a slew of bleak economic reports and a profit warning from Best Buy.

  • Investors usually cash out ahead of a holiday weekend and, in this jittery environment, they found their reasons to sell today: a slew of bleak economic reports and a profit warning from Best Buy.

  • 0800213 Pfizer.jpg

    With a 5.6% dividend yield, Pfizer is currently the highest yielding stock in the Dow Jones Industrial Average and ranks 20th in yield on the S&P 500.  As a point of comparison, 30 Yr treasuries and the Lehman Aggregate Bond Index are yielding about 4.5%.  The Lehman Corporate Bond Index is yielding 5.55%. So is it the time to buy PFE?

  • graphic_word_ofthe_street.jpg

    Stocks lost ground Monday, coming off their best week in nearly five years. What's the word on the Street?

  • graphic_word_ofthe_street.jpg

    The Dow gives up a 200-point gain as traders second guess the Fed decision. Fast Money offers some clarity on the future - as well as a ton of after-hours action - in the Word on the Street.

  • Eli Lilly's drug Zyprexa.

    abstract goes here

  • Eli Lilly posted a higher fourth-quarter profit Tuesday. The pharmaceutical firm cited lower taxes and better-than-expected drug sales -- especially sales of its newer formulations for diabetes and cancer. John Lechleiter, president and chief operating officer -- and Lilly's CEO as of April 1 -- gave CNBC his strong earnings outlook.

  • Byetta Needle

    Direct-to-consumer pharmaceutical advertising is everywhere in American media because it works. Generally speaking, it drives patients to ask/tell their doctors to prescribe a particular medication.

  • Eli Lilly Tuesday said fourth-quarter profit rose on lower taxes and better-than-expected sales of its medicines, including its newer treatments for depression, diabetes and cancer.

  • Despite recent market upheavals, Sidney Taurel, CEO of Eli Lilly, says he is not convinced the pharmaceuticals sector will be negatively impacted. “The pharmaceutical industry is not that affected by business cycles, and so I believe this financial and possible economic crisis isn’t going to affect significantly our company or the industry.”

  • The show was over, but Cramer kept going. Don't miss his in-depth answers to audience questions about Merck, Target and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Eli Lilly

    For the second time this week, big pharma is taking a beating from critical reports about medications. This time, it's antidepressants. But one analyst thinks the drag on shares is overdone -- and names "exciting" pharma stocks.

  • merck_logo.jpg

    If or when you watch one of the presidential  debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...

  • In the wake of Pfizer pulling the plug on its poor-selling inhaled insulin Exubera, the world's biggest diabetes drug company, Novo Nordisk is throwing in the towel on development of its version of inhaled insulin.

  • Eli Lilly

    Even though I'm back on the East Coast today I wanted to share what I think is an interesting anecdote from my time Monday at the JPMorgan Healthcare Conference which is wrapping up in San Francisco.

  • biomedtraker.jpg

    BioMed Tracker, which closely monitors the clinical trial and drug approval process for investors, is out with a new report today on the Food and Drug Administration's record last year. The drug approval rate went down 13 percent and the number of "approvable letters" went up a whopping 40 percent. An approvable letter has become a euphemism for "delay."

  • Eli Lilly Tuesday said U.S. regulators approved once-daily use of two low-dose forms of its Cialis anti-impotence drug, offering greater convenience for men expecting frequent sexual activity.

  • tomorrows_playbook_2.jpg

    Alcoa (AA) kicks off earnings season Wednesday after the bell. Which stocks and sectors look the best?

  • CES08_badge.jpg

    Slowdown talk hurts tech, commodities, defense stocks today. UBS downgrades IBM on concerns about a slowing in tech orders; Deutsche Bank downgrades Boeing and Goodrich. Commodities weak across the board—metals, steel, iron ore (2nd day in a row.) Defensive stocks—consumer, drugs all strong. Lilly upgraded at Morgan Stanley.